New clinical follow-up results indicate that a personalized mRNA vaccine may help reduce the risk of melanoma returning. The vaccine, developed by Moderna in collaboration with Merck, is designed for individual patients and is being assessed in a clinical trial that previously evaluated its effects at earlier stages. According to the latest five-year follow-up data reported by multiple outlets, researchers track participants from a Phase 2b study to determine whether the treatment helps prevent cancer recurrence over the long term. The reporting describes melanoma as the deadliest form of skin cancer and frames the findings around lower rates of recurrence among vaccinated participants compared with outcomes expected without the vaccine. The sources emphasize that the results are based on longer-term follow-up, extending the observation window to five years after enrollment in the earlier trial. The information presented focuses on the vaccine’s potential benefit in reducing how often melanoma returns, rather than on any new safety concerns or regulatory decisions.